Pacer Advisors Inc. Has $4.39 Million Stock Position in Becton, Dickinson and Company $BDX

Pacer Advisors Inc. cut its holdings in shares of Becton, Dickinson and Company (NYSE:BDX) by 26.8% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,469 shares of the medical instruments supplier’s stock after selling 8,593 shares during the period. Pacer Advisors Inc.’s holdings in Becton, Dickinson and Company were worth $4,393,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors also recently modified their holdings of the company. BSW Wealth Partners bought a new position in Becton, Dickinson and Company in the third quarter valued at approximately $340,000. Marshall & Sullivan Inc. WA lifted its stake in shares of Becton, Dickinson and Company by 1.7% in the 3rd quarter. Marshall & Sullivan Inc. WA now owns 19,769 shares of the medical instruments supplier’s stock valued at $3,700,000 after purchasing an additional 332 shares during the period. Harbor Capital Advisors Inc. boosted its position in shares of Becton, Dickinson and Company by 2.6% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 4,842 shares of the medical instruments supplier’s stock worth $906,000 after purchasing an additional 125 shares during the last quarter. World Investment Advisors grew its stake in shares of Becton, Dickinson and Company by 4.8% during the third quarter. World Investment Advisors now owns 20,157 shares of the medical instruments supplier’s stock worth $3,773,000 after purchasing an additional 918 shares during the period. Finally, Brookstone Capital Management increased its holdings in Becton, Dickinson and Company by 16.6% in the third quarter. Brookstone Capital Management now owns 22,737 shares of the medical instruments supplier’s stock valued at $4,256,000 after purchasing an additional 3,237 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Trading Down 0.7%

Shares of NYSE:BDX opened at $195.02 on Tuesday. The firm has a market cap of $55.56 billion, a price-to-earnings ratio of 33.45, a PEG ratio of 1.81 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $162.29 and a 12 month high of $251.99. The company’s fifty day simple moving average is $190.44 and its 200 day simple moving average is $186.52. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The firm had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.42% and a net margin of 7.68%. As a group, research analysts forecast that Becton, Dickinson and Company will post 14.43 EPS for the current fiscal year.

Becton, Dickinson and Company Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Shareholders of record on Monday, December 8th will be paid a $1.05 dividend. This represents a $4.20 annualized dividend and a yield of 2.2%. The ex-dividend date is Monday, December 8th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 72.04%.

Analyst Ratings Changes

A number of brokerages have issued reports on BDX. Argus raised their target price on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $202.00 to $210.00 and gave the stock a “sector perform” rating in a research note on Wednesday, December 17th. Morgan Stanley increased their target price on shares of Becton, Dickinson and Company from $197.00 to $210.00 and gave the stock an “overweight” rating in a report on Tuesday, December 2nd. Jefferies Financial Group lifted their price target on shares of Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a research report on Wednesday, December 10th. Finally, Piper Sandler dropped their price objective on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research note on Friday, November 7th. Four research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Becton, Dickinson and Company has an average rating of “Hold” and an average price target of $205.64.

Insider Buying and Selling

In other Becton, Dickinson and Company news, EVP Michael David Garrison sold 629 shares of the company’s stock in a transaction that occurred on Wednesday, December 17th. The stock was sold at an average price of $196.03, for a total transaction of $123,302.87. Following the completion of the transaction, the executive vice president owned 13,105 shares of the company’s stock, valued at $2,568,973.15. This represents a 4.58% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bertram L. Scott sold 217 shares of Becton, Dickinson and Company stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $176.58, for a total transaction of $38,317.86. Following the completion of the sale, the director owned 35,816 shares in the company, valued at $6,324,389.28. This trade represents a 0.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 1,052 shares of company stock valued at $201,235. Insiders own 0.40% of the company’s stock.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.